

2-19-2020

## Isolated Forefoot Juvenile Xanthogranuloma: Unique Case Study and Treatment in a Pediatric Patient

Brian Derner DPM

*HCA Healthcare*, [brianderner@healthonecares.com](mailto:brianderner@healthonecares.com)

Kristine Hoffman

[kristine.hoffman@ddha.org](mailto:kristine.hoffman@ddha.org)

Amy Storfa MD

Dustin Kruse DPM

*HCA Healthcare*, [Dustin.Kruse@HealthONECares.com](mailto:Dustin.Kruse@HealthONECares.com)

Paul A. Stone DPM, FACFAS

*HCA Healthcare*, [Paul.Stone@HealthONECares.com](mailto:Paul.Stone@HealthONECares.com)

Follow this and additional works at: <https://scholarlycommons.hcahealthcare.com/podiatry>



Part of the [Hemic and Lymphatic Diseases Commons](#), [Pathology Commons](#), [Podiatry Commons](#), and the [Skin and Connective Tissue Diseases Commons](#)

---

### Recommended Citation

Derner BS, Hoffman K, Storfa A, Kruse D, Stone P. Isolated Forefoot Juvenile Xanthogranuloma: Unique Case Study and Treatment in a Pediatric Patient. Poster presented at: ACFAS 2020; February 19-22, 2020; San Antonio, TX.

This Poster is brought to you for free and open access by the Research & Publications at Scholarly Commons. It has been accepted for inclusion in Podiatry by an authorized administrator of Scholarly Commons.



# Isolated Forefoot Juvenile Xanthogranuloma: Unique Case Study And Treatment In A Pediatric Patient

**Brian S. Derner DPM<sup>1</sup>, Kristine Hoffman DPM, FACPAS<sup>2</sup>, Amy Storfa MD<sup>3</sup>, Dustin Kruse DPM, FACPAS<sup>2,4</sup>, Paul Stone DPM, FACPAS<sup>2,5</sup>**

*1. Resident, Highlands-Presbyterian St. Luke's Podiatric Surgical Residency Program, 2. Faculty, Highlands-Presbyterian St. Luke's Podiatric Surgical Residency Program, 3. Pathologist, Denver Health Medical Center 4. Director of Research, Highlands-Presbyterian St. Luke's Podiatric Surgical Residency Program, 5. Program Director, Highlands-Presbyterian St. Luke's Podiatric Surgical Residency Program*

## Purpose

Juvenile xanthogranulomas (JXG) are a benign histiocytic cell proliferative disorder in early childhood. They most commonly present within the first two years of life with papular or nodular changes to the skin on the head, neck or upper trunk. Xanthogranulomas are mostly self-limiting, can be singular or multiple, and rarely can infer a systemic disease process<sup>1</sup>. The purpose of this study was to publish a unique finding of an extra-tendinous solitary mass in an otherwise healthy 17-year old, with surgical and medical treatment after diagnosis.

## Literature Review

Juvenile xanthogranulomas are the most common of the non-Langerhans cell histiocytoses<sup>1</sup>. In a large tumor registry comprised of over 24,000 juvenile soft tissue masses, the incidence of JXG is approximately 0.5%. However, this could underrepresent the incidence because some of these diagnoses were made without histological confirmation<sup>2</sup>. Histologically JXG appear with multinucleated giant cells, and spindle cells in the younger population. In more mature tumors, there is an increased lipid composition with Touton giant cells. These immunohistochemically stain positive for Factor XIIIa, CD68, CD163, CD14, and are negative for S100<sup>3</sup>. Clinically, the most common appearance of these masses are nodules in subcutaneous or deep tissue or yellow plaques or papules. Solitary skin lesions are found in 67-71% of all cases, multiple lesions are seen in 7-10% of patients with JXGs<sup>4</sup>.

Treatment is typically performed with excisional biopsy and treatment, most of these lesions are self-limiting and the majority resolve on their own through childhood<sup>5</sup>. Most resolve into hyperpigmented lesions, which are asymptomatic. Surgical intervention is indicated when conservative care fails, or the lesions appear malignant in nature. Rarely, these cases have systemic manifestations, but associated conditions to JXG are neurofibromatosis type 1 (NF-1) or juvenile myelomonocytic leukemia<sup>9,10</sup>.



**Figure 1.**  
Normal AP  
radiographic view



**Figure 2.**  
A. Axial PD fat  
saturated MRI  
B. Coronal PD fat  
saturated MRI  
C. Sagittal T2 MRI


## Case Study

A healthy 17-year-old male presented to clinic with atraumatic 2nd metatarsophalangeal joint (MTPJ) pain on his left foot. Physical examination revealed pain to palpation of the plantar 2nd MTPJ with no callus or dermatological abnormalities. There was a negative Lachman's test and no subluxation of the 2nd MTPJ present. Patient had pain on extension of the 2nd MTPJ but passive and active ROM were WNL. End extension was the most painful. Plain film radiographs were taken (Figure 1) which did not show any bony abnormality or signs of predislocation syndrome. Conservative care with modification of shoe gear and orthotics were suggested.

After three months of failed conservative care, the patient returned to clinic and an MRI revealed a 2nd MTP plantar mass measuring 6mm x 6mm x 4mm, directly plantar lateral to the 2nd MTPJ (Figure 2A,B,C). The mass was hypointense on T1, T2, PD and PD fat saturated imaging. At this point in time, the patient electively wanted to undergo soft tissue mass removal. Surgical intervention was successful and a well circumscribed nodule measuring 1.1 x 0.8 x 0.6 cm was removed.


Pathological evaluation included hematoxylin and eosin (H&E) (Figure 3) and CD68 immunohistochemical staining (Figure 4). After positive CD68 staining and foam cells seen on H&E staining, the mass was diagnosed as a tuberous xanthoma. A lipid panel was then ordered for the patient to determine if he had familial hypercholesterolemia. Under the American Heart Association, he did not have familial hypercholesterolemia and was not put on statin therapy despite an elevated cholesterol level. The pathologic specimen was then sent to Brigham and Women's hospital (Boston, MA) and further evaluated. It was shown to have stained negative for S100, and positive for PU.1 and CD163. This showed there were bland histiocytes and no signs of malignancy. The final pathologic diagnosis was determined to be xanthogranuloma with infarction.

The patient was followed for one year and postoperatively healed his incision at three weeks with no signs of infection. Patient progressed to weight bearing as tolerated and was back to his previous activity level at three months. There were no complications in his follow up period.



**Figure 3. (Left)** Hematoxylin and eosin staining with foam cells

**Figure 4. (Right)** CD 68 positive immunohistochemical stained image of the soft tissue mass



## Analysis and Discussion

Although exceedingly rare, the majority of these lesions are self-limiting and resolve in the pediatric patient population. Two large case series have been performed for JXG. Dehner's study of 174 JXG lesions showed that only about 16% of masses were in the lower extremity, and four on the lower leg. With complete excisional biopsy, there was a 0% recurrence rate<sup>4</sup>. Janssen and Harms, in their study of 129 patients with JXG, showed only a 10% incidence on the lower extremity and only 2 patients with lesions on the sole of their foot. Their recurrence rate was 7% with total excision of the solitary masses. These recurrences were in the same surgical site and did not migrate<sup>2</sup>. More recently, there are scant case studies of juvenile xanthogranulomas on the soles of the feet, posterior heel and only one case subcutaneously of the 1<sup>st</sup> metatarsophalangeal joint<sup>6-8</sup>.

In conclusion, we present a unique soft tissue tumor with a very unique presentation from the majority of JXG's in the literature. There was no dermatological component, the patient was slightly older than the average patient population, and the patient was relatively normolipidemic. We hope this adds to the body of literature and urge foot and ankle surgeons to use a medical team approach if they were to ever encounter one of these rare tumors.

## References

1. Weitzman S, Jaffe R. Uncommon histiocytic disorders: the non-Langerhans cell histiocytoses. *Pediatr Blood Cancer*. 2005;45(3):256-264. doi:10.1002/pbc.20246
2. Janssen D, Harms D. Juvenile xanthogranuloma in childhood and adolescence: a clinicopathologic study of 129 patients from the kiel pediatric tumor registry. *Am J Surg Pathol*. 2005;29(1):21-28. doi:10.1097/01.pas.0000147395.01229.06
3. Hernandez-Martin A, Baselga E, Drolet BA, Esterly NB. Juvenile xanthogranuloma. *J Am Acad Dermatol*. 1997;36(3 Pt 1):355-367. quiz 368-369. doi:10.1016/s0190-9622(97)80207-1
4. Dehner LP. Juvenile xanthogranulomas in the first two decades of life: a clinicopathologic study of 174 cases with cutaneous and extracutaneous manifestations. *Am J Surg Pathol*. 2003;27(5):579-593. doi:10.1097/0000478-200305000-00003
5. Isaacs H. Fetal and neonatal histiocytoses. *Pediatr Blood Cancer*. 2006;47(2):123-129. doi:10.1002/pbc.20725
6. Motegi S, Nagai Y, Amano H, Tamura A, Ishikawa O. An unusual presentation of juvenile xanthogranuloma. *Pediatr Dermatol*. 2007;24(5):576-577. doi:10.1111/j.1525-1470.2007.00531.x
7. Kaneshiro S, Shi K, Ebina K, Yukioka M, Yoshikawa H, Murata N. Multiple subcutaneous xanthogranuloma at joint-articular sites with bone cystic changes resembling rheumatoid arthritis: A case report. *Modern Rheumatology*. 2018;28(2):361-364. doi:10.3109/14397595.2015.1109763
8. Whittam LR, Higgins EH. Juvenile xanthogranuloma on the sole. *Pediatr Dermatol*. 2000;17(6):460-462. doi:10.1046/j.1525-1470.2000.01822.x
9. Burgdorf WHC, Zelger B. JXG, NF1, and JMML: alphabet soup or a clinical issue? *Pediatr Dermatol*. 2004;21(2):174-176. doi:10.1111/j.0736-8046.2004.21219.x
10. Cambiaghi S, Restano L, Caputo R. Juvenile xanthogranuloma associated with neurofibromatosis 1: 14 patients without evidence of hematologic malignancies. *Pediatr Dermatol*. 2004;21(2):97-101. doi:10.1111/j.0736-8046.2004.21201.x

Financial Disclosures: None for this poster

This research was supported (in whole or in part) by HCA and/or an HCA affiliated entity. The views expressed in this publication represent those of the author(s) do not necessarily represent the official views of HCA or any of its affiliated entities.